EUSA Pharma Signs Exclusive Distribution Agreement with Samaritan for Anesthetic Pain Patch to Launch and Sell in Greece and Cyprus
Samaritan Pharmaceuticals, Inc. has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus.
Las Vegas, NV, January 03, 2008 --(PR.com)-- Rapydan Boosts Sales Arm Pipeline to Eleven Revenue Generating Specialty Products
Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce that it has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus.
Rapydan provides a Controlled Heat-Assisted Drug Delivery (CHADD) technology that allows for the targeted, rapid and deep anesthetic effect of Lidocaine and Tetracaine. The topically administered patch contains a heating element that warms the surface temperature of the skin instigating a vasodilatory effect; consequently, two major benefits are observed: the rapid onset of anesthesia and the increased accessibility of blood vessels.
Rapydan is indicated for surface anesthesia of the skin in connection with needle puncture in adults and children, and in cases of superficial surgical procedures on normal intact skin in adults.
Visit the RAPYDAN website: www.rapydan.net
Visit List of In-licensed Products: http://www.samaritanpharma.com/marketed_products.asp
Samaritan Pharmaceuticals: ``Transforming Today's Science Into Tomorrow's Cures...''
Samaritan Pharmaceuticals is a life science company focused on commercializing its pipeline of innovative drugs to relieve the suffering of patients with Alzheimer's, cancer, heart disease, and infectious disease. Samaritan's business strategy is to partner drug candidates in its pipeline after Phase II (proof of concept) human studies. Samaritan has executed its first partnering agreement with Pharmaplaz, Ireland for its PII, HIV drug SP-01A. In addition, Samaritan's sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in Greece and various Eastern European countries.
Disclaimer
The company disclaims any information created by an outside party and endorses only information communicated by its press releases, filings, and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
###
Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce that it has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus.
Rapydan provides a Controlled Heat-Assisted Drug Delivery (CHADD) technology that allows for the targeted, rapid and deep anesthetic effect of Lidocaine and Tetracaine. The topically administered patch contains a heating element that warms the surface temperature of the skin instigating a vasodilatory effect; consequently, two major benefits are observed: the rapid onset of anesthesia and the increased accessibility of blood vessels.
Rapydan is indicated for surface anesthesia of the skin in connection with needle puncture in adults and children, and in cases of superficial surgical procedures on normal intact skin in adults.
Visit the RAPYDAN website: www.rapydan.net
Visit List of In-licensed Products: http://www.samaritanpharma.com/marketed_products.asp
Samaritan Pharmaceuticals: ``Transforming Today's Science Into Tomorrow's Cures...''
Samaritan Pharmaceuticals is a life science company focused on commercializing its pipeline of innovative drugs to relieve the suffering of patients with Alzheimer's, cancer, heart disease, and infectious disease. Samaritan's business strategy is to partner drug candidates in its pipeline after Phase II (proof of concept) human studies. Samaritan has executed its first partnering agreement with Pharmaplaz, Ireland for its PII, HIV drug SP-01A. In addition, Samaritan's sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in Greece and various Eastern European countries.
Disclaimer
The company disclaims any information created by an outside party and endorses only information communicated by its press releases, filings, and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
###
Contact
Samaritan Pharmaceuticals
Tom Vosicky
702-735-7001
www.samaritanpharma.com
Tom Vosicky
702-735-7001
www.samaritanpharma.com
Contact
Categories